Team Of Max Planck Scientists Elucidates Structure Of A Protein Segment Involved In 'Von Recklinghausen Neurofibromatosis'

August 14, 1998

Scientists at the Max Planck Institute for Molecular Physiology in Dortmund and of the Max Planck Institute for Medical Research in Heidelberg (Germany) have determined the first structure of a functional protein unit that is involved in the development of ‘von Recklinghausen neurofibromatosis’. This unit is a regulator of another protein involved in the pathogenesis of numerous tumors, linking neurofibromatosis to tumor development. The work, published in the August 3, 1998, issue of EMBO Journal, confirms mechanistic ideas about the function of this protein stemming from the authors' fundamental structural and biochemical studies of the related protein p120GAP (Mittal et al., 1996, Science 273, 115-117; Scheffzek et al., 1996, Nature 384, 591-596; Scheffzek et al., 1997, Science 277, 333-338; Ahmadian et al., 1997, Nature Struct. Biol. 4, 686-689).

von Recklinghausen neurofibromatosis, also called type 1 neurofibromatosis or simply NF1, is an inherited disease that predisposes the formation of certain types of tumors and may be associated with a number of other symptoms including learning disabilities and mental retardation. So-called Lish nodules of the iris or pigmentation abnormalities of the skin (so-called ‘café-au-lait spots’) and neurofibromas, benign cutaneous tumors, are hallmarks of NF1 with important diagnostic relevance. In rare cases, NF1 may develop into malignant tumors.

The so-called NF1 gene is responsible for the development of the disease. It codes a huge protein, termed neurofibromin, comprising nearly 3000 amino acids, and it is disrupted or mutated in patients affected with NF1. A segment comprising ca. 10% of the whole protein represents the only known functional module of neurofibromin. It functions as a negative regulator of Ras, another protein that is intimately involved in the regulation of cell growth and differentiation. The physiological importance of this is underscored by the observation that Ras carries characteristic mutations in 30% of all cancer tumors.

Ras can be thought of as a binary signal switch cycling between ON and OFF states which are characterized in terms of a small molecule, a guanine nucleotide, bound to the protein. In the resting cell, Ras is tightly bound to guanosine diphosphate (GDP), which is exchanged for guanosine triphosphate (GTP) upon binding of extracellular stimuli to cell membrane receptors. In the GTP-bound form, Ras interacts specifically with so-called effector proteins, thereby initiating cascades of protein-protein interactions that may finally lead to cell proliferation. To return to the inactive OFF state, Ras cleaves off the terminal phosphate moiety, the g -phosphate, of GTP in an enzymatic process, the intrinsic GTPase reaction. The remaining GDP-bound Ras is no longer able to interact with effectors, it is switched OFF. The process of GTP cleavage is very slow: Ras splits one GTP every 30 minutes. But upon interaction with neurofibromin, the rate is enhanced 100,000 fold: the underlying process is termed GTPase activation, making neurofibromin a GTPase activating protein (GAP). A common feature of the Ras mutations found in tumors is the inability of the resulting Ras proteins to cleave GTP efficiently, i.e. to turn off the switch; in addition they are not sensitive to GTPase activation by neurofibromin. Thus, understanding neurofibromin function also means understanding aspects of Ras function, linking NF1 to cancerogenesis.

Apart from neurofibromin, there are other GTPase activating proteins specific for Ras; in living organisms, it is indeed common that identical processes are carried out by different components. The first GAP to be discovered was the p120GAP (Trahey & McCormick, 1987, Science 238, 542-545). In fundamental studies involving biochemical and structural methods, the research team has previously included p120GAP to elucidate the molecular mechanism behind the GTPase activation process. p120GAP, represented by the segment of the protein that is sufficient to stimulate Ras-mediated GTP hydrolysis, complements the active site which is where the reaction takes place. It does so by two strategies: Firstly, it supplies an amino acid (an arginine) that participates directly in the reaction; its mutation to another amino acid destroys GAP activity. Secondly, it stabilizes the functionally most important amino acids on Ras, thereby aligning the catalytic machinery (Scheffzek et al., Science 277, 333-338).

The structure of neurofibromin GAP resembles the structure of the corresponding segment of p120GAP: it is an elongated molecule that is composed of a small and a large domain, the latter of which contains all the functionally important residues. Together with the biochemical analyses, the structural similarity confirms that it functions by the same mechanism. On the basis of the structural work on neurofibromin and p120GAP complexed with Ras, the effect of mutations in the GAP segment, as found in NF1-patients, can be analyzed; e.g. the catalytic arginine contributed by GAP has been found mutated in an NF1 patient; the resulting GAP protein has an intact structure but is completely inactive (Klose et al., 1998, Hum. Mol. Genet. 7, 1261-1268). Since this mutation was the only one found in the whole NF1 gene of the respective patient, it appears that loss of GAP function is sufficient for the development of neurofibromatosis. The medical impact of the work on neurofibromin and p120GAP is twofold: on the one hand it is now possible to picture how neurofibromin acts on Ras and to analyze mutations in the light of the structure; on the other hand, the structure of the contact area between GAP and Ras suggests that it might be attractive to search for small molecules that may act as surrogate GAPs in tumor cells where Ras is fatally mutated or its GTP-bound levels are increased for other reasons, e.g. due to a missing neurofibromin function. The 3-dimensional picture of GAP and of its communication with Ras may suggest how to proceed, but also indicates us that it will be an extremely formidable task.
-end-


Max-Planck-Gesellschaft

Related Amino Acids Articles from Brightsurf:

Igniting the synthetic transport of amino acids in living cells
Researchers from ICIQ's Ballester group and IRBBarcelona's Palacín group have published a paper in Chem showing how a synthetic carrier calix[4]pyrrole cavitand can transport amino acids across liposome and cell membranes bringing future therapies a step closer.

Microwaves are useful to combine amino acids with hetero-steroids
Aza-steroids are important class of compounds because of their numerous biological activities.

New study finds two amino acids are the Marie Kondo of molecular liquid phase separation
a team of biologists at the Advanced Science Research Center at The Graduate Center, CUNY (CUNY ASRC) have identified unique roles for the amino acids arginine and lysine in contributing to molecule liquid phase properties and their regulation.

Prediction of protein disorder from amino acid sequence
Structural disorder is vital for proteins' function in diverse biological processes.

A natural amino acid could be a novel treatment for polyglutamine diseases
Researchers from Osaka University, National Center of Neurology and Psychiatry, and Niigata University identified the amino acid arginine as a potential disease-modifying drug for polyglutamine diseases, including familial spinocerebellar ataxia and Huntington disease.

Alzheimer's: Can an amino acid help to restore memories?
Scientists at the Laboratoire des Maladies Neurodégénératives (CNRS/CEA/Université Paris-Saclay) and the Neurocentre Magendie (INSERM/Université de Bordeaux) have just shown that a metabolic pathway plays a determining role in Alzheimer's disease's memory problems.

New study indicates amino acid may be useful in treating ALS
A naturally occurring amino acid is gaining attention as a possible treatment for ALS following a new study published in the Journal of Neuropathology & Experimental Neurology.

Breaking up amino acids with radiation
A new experimental and theoretical study published in EPJ D has shown how the ions formed when electrons collide with one amino acid, glutamine, differ according to the energy of the colliding electrons.

To make amino acids, just add electricity
By finding the right combination of abundantly available starting materials and catalyst, Kyushu University researchers were able to synthesize amino acids with high efficiency through a reaction driven by electricity.

Nanopores can identify the amino acids in proteins, the first step to sequencing
While DNA sequencing is a useful tool for determining what's going on in a cell or a person's body, it only tells part of the story.

Read More: Amino Acids News and Amino Acids Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.